Dear Editor, Elter et al. recently published in your journal a comprehensive report on the management of infectious risk during treatment by alemtuzumab [1] . Their paper referred exclusively to chronic lymphocytic leukemia patients. Marrow failure syndromes are a group of hematological disorders sharing an immune pathophysiology and may benefit from intense immunosuppressive treatment including antilymphocyte antibodies, such as heterologous antithymocyte globulin (ATG), and cyclosporine A (CyA) [2] . However, given its potent lympholytic effect, alemtuzumab may also be appropriate for patients requiring intense immunosuppression. We recently developed an alemtuzumab-based immunosuppressive treatment for patients suffering from aplastic anemia or singlelineage bone marrow failure disorders [3] , with the aim of inducing a more potent and prolonged immunosuppression and allowing retreatment in case of relapse (retreatment is difficult to attempt when using heterologous antisera). We wish to add our own experience in this particular setting, with specific attention to prophylaxis of cytomegalovirus (CMV) reactivation, which remains a major problem limiting a broader use of alemtuzumab.
A cohort of consecutive patients suffering from either severe aplastic anemia (SAA), pure red cell aplasia (PRCA) or pure white cell aplasia (PWCA) were enrolled in a prospective phase II clinical trial with alemtuzumabbased immunosuppression (EUDRACT number 2008-001151-22). The drug was administered subcutaneously as a single course, at 3-10-30-30-(30) mg doses on four (five) consecutive days (non-SAA patients received the 4-day dose), followed by low-dose (1 mg/kg) cyclosporine A starting from day 7; retreatment by alemtuzumab (as complete courses or single shoots) was allowed in case of relapse. Anti-CMV prophylaxis was administered per protocol to all seropositive patients starting day 7, using oral valganciclovir at the dose of 450 mg, bidaily. Initially, anti-CMV prophylaxis was scheduled until CD4+ T cells reached 250 per microliter; however, since after assessment of immune reconstitution performed in the first patients CD4+count sometimes remained below the planned cutoff for many months, the protocol was amended to withdraw valganciclovir at CD4+ levels above 100 per microliter, and in any case 3 months after treatment. All patients received also anti-Pneumocystisjiroveci prophylaxis by low-dose oral trimethoprimsulfamethoxazole (bidaily three times per week), as well as standard antibacterial and antifungal prophylaxis in case of severe (<500 per microliter) neutropenia. Twentythree consecutive patients were enrolled in the study (ten SAA, ten PRCA, and three PWCA) and received a total of 45 courses of alemtuzumab; additional courses were given in five SAA, four PRCA, and one PWCA patients who relapsed after responding to the initial treatment. All patients received prophylactic valganciclovir because they were CMV IgG seropositive. All patients showed complete lymphoablation within 2-3 days, which lasted several months. CMV antigenemia was monitored weekly by polymerase chain reaction (PCR), to be ready for preemptive therapy; CMV reactivation was defined as a positive PCR (detection limit 1,000 copies per milliliter) in two consecutive samples. After a cumulative follow-up of 222 patient-months (median follow-up of 12 months), no patient developed symptoms possibly related to CMV reactivation, such as lymphadenopathy; two patients had an episode of fever of unknown origin, which was considered not related to CMV given a negative antigenemia. Asymptomatic CMV reactivation, just above the detection limit of our sensitive PCR, occurred during follow-up in three patients who had discontinued valganciclovir (after at least 3 months of treatment); in these patients, valganciclovir was reused as preemptive treatment, leading to prompt viremia clearance. In the whole cohort, a single patient required lamivudine for HBV reactivation; other viral complications were irrelevant: two patients with herpes simplex virus (very early, before starting valganciclovir), one with late varicella zoster virus with shingles (occurring when the patients had already discontinued valganciclovir), and one with flu, all resolving quickly.
In the standard immunosuppressive treatment for SAA (ATG and CyA), immune reconstitution is usually sufficiently rapid to avoid the risk of clinically relevant CMV reactivation [4] . Alemtuzumab has been scarcely investigated in bone marrow failure syndromes given the specific risk of opportunistic infection from viruses (especially CMV reactivation) and other intracellular pathogens [1, [5] [6] [7] that would synergize and increase the risk of bacterial complications due to the concomitant neutropenia, especially in SAA. Another concern could be the fear of marrow toxicity deriving from both CMV reactivation and anti-CMV agents. Various antiviral agents have been utilized for the prevention or treatment of CMV-related complications in immunocompromised patients, including ganciclovir [8] and its oral prodrug valganciclovir [9] . In a recent randomized trial [10] , oral valganciclovir has proven to be more effective than valaciclovir in eliminating the risk of CMV reactivation in patients receiving alemtuzumab for a lymphoproliferative disorder. In our study, we provide evidence that oral valganciclovir is effective in preventing CMV reactivation, even in severely immunocompromised patients as those suffering from bone marrow failure. At the dose used, valganciclovir did not exert any toxic effect on hematopoietic stem cells: hematopoietic recovery was consistent with the response rate and speed expected for such diseases (manuscript in preparation). In conclusion, while fully agreeing with Elter's conclusions that alemtuzumab treatment deserves an adequate management of infectious risk [1] , we have shown that a CMV reactivation prophylaxis may allow the use of alemtuzumab in diseases traditionally considered too risky for such a therapy. We provide evidence that oral valganciclovir is effective as anti-CMV prophylaxis in the specific setting of bone marrow failure patients; the optimal duration of treatment as tailored on CD4+ recovery needs to be assessed in larger confirmatory studies.
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